Fisherman who killed bottlenose dolphins sentenced to a month in jail
A Florida charter boat captain will pay a $51,000 fine and spend a month in jail for killing bottlenose dolphins in the Gulf of Mexico, according to a sentence handed down last week by a federal district judge.
Zachary Brandon Barfield's sentencing by Magistrate Judge Michael J. Frank of the U.S. District Court for the Northern District of Florida followed a plea deal with prosecutors on three counts of violating the Marine Mammal Protection Act stemming from the shooting and poisoning of dolphins.
The guilty plea followed a two-year investigation by NOAA Fisheries and the Florida Fish and Wildlife Conservation Commission after a law enforcement agent in 2023 received a tip that a fisherman was killing bottlenose dolphins in waters in the northern Gulf of Mexico, which President Donald Trump recently renamed the Gulf of America.
Advertisement
According to a statement of facts filed into the court record, Barfield, whose business operated out of Panama City, inserted a deadly insecticide called methomyl into baitfish using paper towels to deter dolphins from eating red snapper off fishing lines. He later fired a shotgun five times at dolphins near his fishing vessel, killing one, according to court filings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
20 minutes ago
- Fox News
The Five - Wednesday, June 4
All times eastern Legends & Lies: The Real West FOX News Radio Live Channel Coverage
Medscape
29 minutes ago
- Medscape
Patients With HS, Obesity Report Improvements With GLP-1 RAs
In a survey of 22 patients with hidradenitis suppurativa (HS), more than two thirds reported symptom improvement after treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs). METHODOLOGY: Researchers conducted a cross-sectional survey of 22 adults (average age, 45 years; 90.9% women) with HS who were treated with GLP-1 RAs at the University of Pennsylvania's Dermatology Department between January 2019 and August 2024. Most participants were non-Hispanic (90.9%), 54.5% were Black, and 36.4% were White; 89.5% were classified as overweight or having obesity. GLP-1 RAs prescriptions were semaglutide (40.9%), tirzepatide (36.4%), dulaglutide (18.2%), or liraglutide (4.5%), with an average treatment duration of 17 months (range, 2-108 months). Primary outcomes were HS severity and quality of life. TAKEAWAY: Most participants (77.3%) achieved weight loss averaging 31 lb; 68.2% reported improvement in HS-specific health, while 31.8% reported no change in their condition. Patient-reported symptom improvements included reduced flares (61.9%), new lesions (66.7%), pain (52.4%), drainage (61.9%), itch (47.6%), and odor (42.9%). Common side effects included gastrointestinal symptoms, allergic reactions, headaches, menstrual spotting, and appetite suppression. Nearly 60% of patients reported that HS had less impact on their daily activities, with the same percentage stating they would recommend GLP-1 RAs to other patients. IN PRACTICE: 'These data suggest GLP-1 RAs may play an important adjunctive role in the treatment of HS, particularly given the high prevalence of obesity and diabetes in the HS population,' the study authors wrote. 'Randomized controlled studies with robust patient and dermatologist-reported endpoints,' they added, 'are needed to confirm these findings and establish clinical guidelines for use of GLP-1 RAs' in HS. SOURCE: The study was led by Radhika Gupta, BA, University of Pennsylvania, Philadelphia. It was published online on May 29 in JAAD International . LIMITATIONS: Study limitations included small size, lack of clinician assessment, high nonresponse rate, and potential recall bias. DISCLOSURES: The study received funding through a philanthropic gift for HS research. Gupta disclosed being a consultant for Cabaletta Bio. One author reported receiving research funding from Amgen, Boehringer Ingelheim, Cabaletta Bio, and InflaRx. Another author reported being a consultant for Sonoma Biotherapeutics, and the fourth author reported being a consultant for Vertex Pharmaceuticals.
Washington Post
32 minutes ago
- Washington Post
Vigil held for victims of Boulder firebombing attack as suspect's family fights deportation
BOULDER, Colo. — Hundreds of people squeezed into the Jewish Community Center in Boulder, Colorado, for a vigil that featured prayer, singing and emotional testimony from a victim and witnesses of the firebombing attack in the city's downtown , while a federal judge has blocked the deportation of the suspect's family.
